KAG-308 is a potent, selective, and orally active agonist of the EP4 receptor, a prostaglandin E2 receptor subtype. It suppresses colitis, promotes histological mucosal healing, and potently inhibits TNF-α production. This compound exhibits high selectivity for the human EP4 receptor with a Ki of 2.57 nM and an EC50 of 17 nM, demonstrating greater selectivity over EP1, EP2, EP3, and IP receptors.
- Potent, selective, and orally active agonist of the EP4 receptor
- Suppresses colitis and promotes histological mucosal healing
- Potently inhibits TNF-α production
- Shows greater selectivity over EP1, EP2, EP3, and IP receptors
- Exhibits potent agonist activity for human and mouse EP4